Adcentrx Therapeutics Inc. has received FDA clearance of its IND application for ADRX-0405 for the treatment of select advanced solid tumors. A first-in-human phase Ia/b trial of ADRX-0405 in patients with select advanced solid tumors, including metastatic castration-resistant prostate cancer, will begin enrollment and dosing this quarter.
Investigators from the University of Michigan and affiliated organizations published data from a study that aimed to investigate the role of cyclin-dependent kinase 12 (CDK12) in prostate cancer (PCa). Both in vivo and in vitro systems were developed to test the impact of Cdk12 ablation in the context PCa.
Xuanzhu Pharma Co. Ltd. has divulged cholesterol side-chain cleavage enzyme, mitochondrial (CYP11A1) inhibitors reported to be useful for the treatment of castration-resistant prostate cancer.
Prostate cancer accounts for 3.8% of total cancer-related deaths worldwide. The combination of docetaxel and androgen deprivation therapy is useful in the management of the disease, but unfortunately, prostate cancer cells become resistant to docetaxel over time.
Clarity Pharmaceuticals Ltd. will begin early next year its pivotal phase III trial for its copper-based radiopharmaceutical, 64Cu-SAR-bisPSMA, for diagnosing prostate cancer in patients with biochemical recurrence following positive U.S. FDA feedback.
Genetic Intelligence Inc. has described compounds acting as IL-2 expression or activity modulators reported to be useful for the treatment of cancer, infections, autoimmune diseases and inflammatory disorders.
EZH2 and LSD1 are histone modification enzymes often overexpressed in several types of aggressive cancer such as colorectal, breast or prostate cancer, among others.
Cyclin-dependent kinases 12 and 13 (CDK12 and CDK13) are involved in the regulation of transcription elongation, DNA damage response and genomic stability balance. A few inhibitors of CDK12- and CDK13-mediated transcription have shown antiproliferative effects in the preclinical setting but have not progressed to clinical testing due to excessive toxicity.
Astrazeneca AB has divulged proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase cereblon unit coupled to an androgen receptor (AR) targeting moiety via a linker acting as AR degradation inducers reported to be useful for the treatment of cancer.
Researchers from Imperial College London presented data from a study that aimed to assess the role of miR-1271-5p in prostate cancer (PCa) progression.
